Introduction

Macrocytic anemia is one of the most common patterns seen on a routine blood test, and it sits at a useful crossroads in medicine. The same lab finding can point to something as simple as a vegan diet or as serious as a bone marrow neoplasm.

Two things must be present for a diagnosis of macrocytic anemia. First, anemia itself: a low hemoglobin or hematocrit. Second, macrocytosis: red blood cells that are abnormally large, defined as MCV greater than 100 fL on a complete blood count (CBC). Macrocytosis on its own is not a disease; it is a signal that something is interfering with how the bone marrow makes red blood cells.

This matters in real life. A patient with undiagnosed B12 deficiency may go on to develop irreversible spinal cord damage. A young adult with a high MCV may be drinking more than they admit. An older patient with a refractory macrocytic anemia may have a myelodysplastic neoplasm that needs prompt referral. Each story starts with the same lab value.

Why MCV Matters

MCV measures the average size of red blood cells. It is one of the fastest ways to narrow down the cause of an anemia. Anemias sort into three buckets based on MCV:

• Microcytic anemia (MCV below about 80 fL): smaller-than-normal cells. Iron deficiency anemia and thalassemia are the usual culprits.
• Normocytic anemia (MCV roughly 80 to 100 fL): normal-sized cells. Common causes include anemia of chronic disease, acute blood loss, and hemolytic anemia.
• Macrocytic anemia (MCV above 100 fL): larger-than-normal cells. Investigate for B12 or folate deficiency, liver disease, alcohol use, thyroid disease, drugs, or myelodysplastic neoplasms.

The rest of this article walks through each cause, the bedside and lab clues that point to it, and how it is managed.

Megaloblastic Anemia

Megaloblastic anemia is the form of macrocytic anemia caused by impaired DNA synthesis in developing red blood cells. The bone marrow keeps trying to produce red cells, but their nuclei mature too slowly. The result is large, immature precursors called megaloblasts, which often die before reaching the bloodstream. This pattern of "nuclear-cytoplasmic asynchrony," where the cytoplasm grows while the nucleus lags, is the defining feature.

Vitamin B12 Deficiency

Vitamin B12 (cobalamin) is essential for DNA synthesis and for maintaining the myelin sheath around nerves. When it runs low, both the bone marrow and the nervous system suffer.

Mechanism. B12 acts as a cofactor for two key enzymes: methionine synthase (which converts homocysteine to methionine) and methylmalonyl-CoA mutase (which converts methylmalonyl-CoA to succinyl-CoA). When B12 is deficient, methylmalonic acid (MMA) builds up and contributes to demyelination, while impaired DNA synthesis produces megaloblastic changes in the marrow [5,6].

Causes.

• Pernicious anemia: an autoimmune destruction of gastric parietal cells that produce intrinsic factor (IF). Without IF, B12 cannot be absorbed in the terminal ileum.
• Dietary insufficiency: seen most often in strict vegans, since B12 occurs almost exclusively in animal-derived foods.
• Malabsorption: gastrectomy, chronic pancreatitis, Crohn's disease, ileal resection, or tropical sprue.
• Medications: long-term proton pump inhibitors (PPIs) and metformin both reduce B12 absorption over time. The American Diabetes Association (ADA) recommends periodic testing of vitamin B12 levels in patients treated with metformin, particularly those with anemia or peripheral neuropathy [8].
• Nitrous oxide exposure: recreational use of nitrous oxide ("whippets") oxidizes cobalamin and causes a functional B12 deficiency, sometimes with severe neurological symptoms even when serum B12 looks normal [7]. This cause is increasingly seen in young adults presenting to emergency departments.

Neurological warning. Unlike other macrocytic anemias, B12 deficiency can cause subacute combined degeneration of the spinal cord. Screen every patient for paresthesia ("pins and needles"), loss of vibration sense, loss of proprioception, and unsteady gait. Damage becomes permanent if the deficiency is not corrected promptly [6].

Clinical clue: the beefy red tongue. Atrophic glossitis, where the tongue loses its papillae and looks smooth, shiny, and red, is a classic sign of B12 deficiency. It usually appears late, so its absence does not rule out the diagnosis.

Management. Intramuscular hydroxocobalamin remains the first-line treatment for newly diagnosed pernicious anemia, severe deficiency, and any patient with neurological involvement [4]. The 2024 NICE guideline recommends initial loading injections followed by lifelong maintenance every 2 to 3 months for pernicious anemia [4]. High-dose oral cobalamin (typically 1 mg daily) is an effective alternative for maintenance in stable patients, because roughly 1 percent of an oral dose is absorbed by passive diffusion without needing intrinsic factor [4].

Folate Deficiency

Folate deficiency is the other major cause of megaloblastic anemia. It shares the hematologic features of B12 deficiency, but progresses faster because the body's folate stores last only weeks to months, not years.

Mechanism. Folate is needed to make the building blocks of DNA (purines and pyrimidines). Specifically, it is required to convert deoxyuridylate (dUMP) into deoxythymidylate (dTMP). Without enough folate, DNA replication stalls, producing the same nuclear-cytoplasmic asynchrony seen in B12 deficiency.

Causes

• Dietary insufficiency: common in elderly patients living alone on a limited "tea and toast" diet. Folate is found in leafy green vegetables, fruits, and fortified grains, and overcooking destroys it.
• Increased demand: pregnancy, lactation, and chronic hemolytic states such as sickle cell disease all raise folate requirements.
• Alcohol use: alcohol blocks folate absorption, impairs hepatic folate metabolism, and increases urinary loss.
• Malabsorption: celiac disease and tropical sprue affect the proximal small intestine where folate is absorbed.

The B12 rule. Folic acid must never be used to treat macrocytic anemia without first checking B12 levels. Treating a hidden B12 deficiency with folate alone can correct the anemia while the neurological damage continues to progress, and may even accelerate it [5,6].

Management. Oral folic acid 1 to 5 mg daily resolves the anemia within weeks. Because folate is water-soluble, toxicity from excess intake is rare.

Non-Megaloblastic Macrocytic Anemia

In these conditions, the macrocytosis comes from changes outside the DNA machinery, often through the red blood cell membrane or through abnormal bone marrow output.

Liver Disease

Chronic liver disease is one of the most frequent causes of non-megaloblastic macrocytosis. Here the cell's outer membrane is the problem, not its DNA.

Mechanism. A diseased liver mishandles lipid metabolism, leading to excess cholesterol and phospholipid deposition on the red blood cell membrane. The extra surface area flattens and enlarges the cell, raising the MCV.

Causes. Cirrhosis from any source (hepatitis C, alcohol, MASH/metabolic dysfunction-associated steatohepatitis), obstructive jaundice, and alcohol-related liver disease are the main contributors. Alcoholic liver disease is particularly tricky because it combines three mechanisms: direct alcohol toxicity, folate deficiency, and lipid-related membrane changes.

Smear clue. Target cells (codocytes) are the hallmark. The excess membrane bunches in the center, producing a bullseye pattern. When target cells dominate a smear, liver disease or a hemoglobinopathy is far more likely than a vitamin deficiency.

Round vs. oval. Megaloblastic macrocytes are typically oval (macro-ovalocytes). Liver-related macrocytes are typically round. This distinction often steers the workup before any specialized testing.

Management. There is no specific treatment for the macrocytosis itself. Treating the underlying liver disease is what matters, and the MCV may only normalize if hepatic lipid metabolism is restored.nge.

Hypothyroidism

Hypothyroidism is a less obvious cause of macrocytic anemia but an important one, since macrocytosis can be the earliest clue to a sluggish thyroid.

Mechanism. Thyroid hormones (T3 and T4) stimulate erythropoiesis. When they fall, the body's oxygen demand drops, marrow activity slows, and the red blood cells produced tend to be larger. Membrane lipid changes, similar to those in liver disease, also play a role.

Causes. Hashimoto's thyroiditis is the most common cause in iodine-sufficient regions. Iatrogenic hypothyroidism (after thyroidectomy or radioactive iodine) and iodine deficiency are also relevant.

The autoimmune cluster. Hashimoto's thyroiditis and pernicious anemia both involve autoimmune destruction and frequently coexist as part of polyglandular autoimmune syndrome. If MCV is very high (above 110 fL) in a hypothyroid patient, B12 deficiency must be excluded before assuming the thyroid alone is responsible.

Threshold. A meaningful proportion of hypothyroid patients show mild macrocytosis, typically with an MCV between 100 and 105 fL. When fatigue and weight gain accompany a rising MCV, a thyroid-stimulating hormone (TSH) test is essential.

Management. Thyroid hormone replacement (levothyroxine) reverses the macrocytosis. MCV usually returns to normal within a few months as the red cell population turns over.

Alcohol Abuse

Chronic alcohol consumption is the most common cause of non-megaloblastic macrocytosis in everyday clinical practice. The MCV often rises before any other lab abnormality appears.

Mechanism. Alcohol drives macrocytosis through several routes:

• Direct marrow toxicity: ethanol and acetaldehyde interfere with erythroid precursor development, producing larger red cells.
• Membrane changes: cholesterol accumulates on the red cell membrane, increasing surface area.
• Nutritional effects: heavy drinkers often have low folate intake, and alcohol blocks folate absorption and increases its urinary loss.

Clinical clues.

• An isolated raised MCV (100 to 110 fL) is sometimes the only abnormality in a heavy drinker and is used as a subtle screen for hidden alcohol use disorder.
• Bone marrow biopsy may show vacuolated precursors in acute alcohol toxicity.
• Heme synthesis can be disturbed, occasionally producing ringed sideroblasts in the marrow.

Threshold and recovery. The marrow-toxic effects of alcohol are reversible. After abstinence, MCV typically returns to normal over 2 to 4 months, roughly matching the lifespan of a red blood cell.

Management. Abstinence and nutritional support are the foundation. Most clinicians prescribe folic acid 1 mg daily as part of standard treatment, given how common combined folate deficiency is in this population. will begin to fall. It typically takes two to four months (roughly the lifespan of a red blood cell) for the MCV to return to normal.

Myelodysplastic Neoplasms (MDS)

Myelodysplastic neoplasms (renamed from myelodysplastic syndromes in the WHO 2022 classification, though the acronym MDS is retained) are clonal bone marrow disorders defined by ineffective hematopoiesis [1]. The bone marrow is busy but produces malformed cells that often die before reaching the blood. MDS should always be considered in an older patient with an unexplained, refractory macrocytic anemia.

Mechanism. Acquired mutations in hematopoietic stem cells block normal maturation. The result is nuclear-cytoplasmic asynchrony similar to megaloblastic anemia, but driven by genetic damage rather than vitamin deficiency. Defective cells that do reach the circulation often appear as large, misshapen macrocytes.

Causes.

• Primary (de novo) MDS: most common in patients over 65, due to accumulated genetic damage.
• Secondary (therapy-related) MDS: seen after prior chemotherapy or radiation for cancers such as lymphoma or breast cancer.

Diagnostic clues. MDS is often suspected when macrocytic anemia fails to respond to B12, folate, or iron supplementation. The blood smear may show pseudo-Pelger-Huët cells (neutrophils with only two lobes shaped like dumbbells or spectacles) and dimorphic red cell populations. Bone marrow aspirate and biopsy remain the diagnostic gold standard, typically showing a hypercellular marrow alongside peripheral cytopenia.

Risk stratification. Prognosis was previously calculated using the Revised International Prognostic Scoring System (IPSS-R). Since 2022, the Molecular IPSS (IPSS-M) has refined this by incorporating mutations across 152 genes alongside clinical variables, and is now the preferred prognostic tool where molecular testing is available [2].

Management. Treatment depends on risk category and symptoms. Options include:

• Supportive care: transfusions and erythropoiesis-stimulating agents (ESAs) for lower-risk disease.
• Luspatercept: an erythroid maturation agent originally approved for lower-risk MDS with ring sideroblasts, and now approved as first-line treatment for anemia in transfusion-dependent, lower-risk MDS more broadly [3].
• Hypomethylating agents: azacitidine and decitabine for higher-risk disease.
• Allogeneic stem cell transplant: the only curative option, reserved for fit, eligible patients.

Artifactual and Other Causes 

Several other clinical scenarios and laboratory phenomena can drive the MCV above 100 fL without involving liver disease, thyroid dysfunction, or a marrow neoplasm.

• Reticulocytosis: Reticulocytes (immature red blood cells) are approximately 20 percent larger than mature erythrocytes. A massive reticulocyte response, such as in autoimmune hemolytic anemia or acute blood loss, will push the overall MCV up, making reticulocytosis a direct, physiological cause of non-megaloblastic macrocytosis.
• Spurious (Artifactual) Macrocytosis: The automated cell counter can be fooled. In cold agglutinin disease, autoantibodies cause red blood cells to clump at room temperature; the analyzer reads a clump as a single, massive cell. Similarly, in severe hyperglycemia (uncontrolled diabetes), hyperosmolar plasma causes red cells to swell with water when mixed with the analyzer's isotonic diluent, falsely elevating the MCV [9].
• Copper Deficiency: This trace mineral deficiency is a dangerous mimic of B12 deficiency. It produces an identical hematological and neurological profile—macrocytic anemia, neutropenia, and myeloneuropathy. It is increasingly seen in patients with a history of bariatric surgery (such as Roux-en-Y gastric bypass) or those with excessive zinc intake, as zinc competes with copper for gastrointestinal absorption (often linked to overuse of zinc supplements or zinc-containing denture creams) [10].
• Pregnancy: Normal pregnancy induces a mild, physiological macrocytosis. The MCV naturally shifts upward (often to 100–105 fL) due to increased erythropoiesis and altered membrane dynamics, independent of folate or B12 status [11].

Drug-Induced Macrocytosis

Several medications raise the MCV. Although many work by impairing DNA synthesis (technically a megaloblastic mechanism), they are grouped clinically with non-megaloblastic causes because the management approach is to manage the drug rather than supplement vitamins.

Mechanism. Most culprits interfere with DNA polymerase or with the metabolism of purines and pyrimidines, producing nuclear-cytoplasmic asynchrony.

Common offenders.

• Hydroxyurea: used in sickle cell disease and myeloproliferative neoplasms; almost always causes macrocytosis (MCV 110 to 130 fL). A rising MCV is sometimes used as a marker of treatment adherence.
• Zidovudine (AZT): an antiretroviral classically associated with extreme macrocytosis, often without significant anemia.
• Methotrexate: inhibits dihydrofolate reductase and mimics folate deficiency.
• Anticonvulsants: phenytoin and valproate interfere with folate metabolism.
• Other chemotherapy: cytarabine, 5-fluorouracil (5-FU), and azathioprine commonly produce large, stressed red cells.
• PPIs and metformin: cause B12 malabsorption over time rather than direct macrocytosis.

The MCV > 130 fL rule. Extreme macrocytosis with MCV above 130 fL is almost always due to a drug (especially hydroxyurea or zidovudine) or a myelodysplastic neoplasm, not a simple vitamin deficiency.

Management. Drug-induced macrocytosis rarely responds to B12 or folate unless a true deficiency coexists. The MCV typically stays elevated while the patient remains on the medication. Treatment is needed only if the patient becomes symptomatically anemic, in which case the dose may need adjustment.

Approach to a Patient with Macrocytic Anemia

A structured approach saves time and avoids missed diagnoses. The workup moves from history and examination through tiered laboratory testing.

Clinical History

• Symptoms of anemia: fatigue, breathlessness on exertion, pallor, palpitations.
• Diet: vegan or vegetarian patterns, "tea and toast" diet, or restrictive eating.
• Alcohol use: quantify carefully; underreporting is common.
• Medications: review for hydroxyurea, methotrexate, anticonvulsants, PPIs, metformin, antiretrovirals, and recent nitrous oxide use.
• Past medical history: previous gastric or ileal surgery, celiac disease, Crohn's disease, autoimmune disease (especially thyroid disease), liver disease.
• Neurological symptoms: tingling, numbness, unsteady gait, memory changes.

Physical Examination

• General: pallor, jaundice, signs of chronic liver disease (spider naevi, palmar erythema).
• Mouth: smooth, red tongue (atrophic glossitis).
• Neurological: vibration sense, proprioception, Romberg's test, gait. These are critical when B12 deficiency is suspected.

Laboratory Investigations

Tier 1: Initial screening

• Complete blood count (CBC): confirms macrocytosis (MCV > 100 fL), measures hemoglobin and hematocrit, and screens for pancytopenia (which suggests MDS or severe B12 deficiency).
• Reticulocyte count: an elevated count points to active marrow response from hemolysis or blood loss (young red cells are themselves larger); a low or inappropriately normal count points to a production problem.
• Peripheral blood smear: oval macrocytes plus hypersegmented neutrophils suggest megaloblastic anemia; round macrocytes plus target cells suggest liver disease; basophilic stippling can indicate lead poisoning or sideroblastic processes.

Tier 2: Nutritional workup

• Serum vitamin B12: below 200 pg/mL is deficient; 200 to 400 pg/mL is a "gray zone" needing further testing.
• Holotranscobalamin (active B12): where available, this is a more sensitive first-line marker of B12 deficiency than total serum B12 [4].
• Serum or red cell folate: red cell folate reflects long-term stores; serum folate fluctuates with recent meals.
• Methylmalonic acid (MMA) and homocysteine: high MMA plus high homocysteine confirms B12 deficiency; normal MMA with high homocysteine points to folate deficiency.
• Serum copper and ceruloplasmin: check in patients presenting with myeloneuropathy and macrocytic anemia when B12 and MMA levels are normal, especially if there is a history of bariatric surgery or high zinc intake [10].

Tier 3: Specialized testing

• Anti-intrinsic factor and anti-parietal cell antibodies: test for pernicious anemia (anti-IF is highly specific; anti-parietal cell is more sensitive).
• TSH: rule out hypothyroidism.
• Liver function tests: check for liver disease or alcohol-related damage (gamma-glutamyl transferase, GGT, is a useful marker for chronic alcohol use).
• Bone marrow aspirate and biopsy: indicated when the cause is unclear or MDS or leukemia is suspected. Allows morphology, cytogenetics, and molecular testing including IPSS-M scoring [2].

Laboratory Summary Table

When to Escalate

Refer urgently when any of the following are present:

• Pancytopenia or refractory macrocytic anemia (suggesting MDS or marrow failure).
• Neurological signs suggesting subacute combined degeneration.
• Symptomatic severe anemia (typically hemoglobin below 7 g/dL, or higher with cardiopulmonary compromise), which may require transfusion.

Frequently Asked Questions (FAQs)

What is macrocytic anemia?

Macrocytic anemia is a type of anemia where the red blood cells are larger than normal. On a complete blood count, this shows up as a mean corpuscular volume (MCV) above 100 femtoliters. The most common causes are vitamin B12 deficiency, folate deficiency, chronic alcohol use, liver disease, hypothyroidism, and bone marrow disorders such as myelodysplastic neoplasms. The condition itself is a clue, not a diagnosis, so finding the underlying cause is essential.

What is the difference between macrocytic and megaloblastic anemia?

Macrocytic anemia simply means red blood cells are larger than normal. Megaloblastic anemia is one specific cause of macrocytic anemia, where DNA synthesis inside developing red blood cells is impaired, usually because of B12 or folate deficiency. All megaloblastic anemias are macrocytic, but not all macrocytic anemias are megaloblastic. Liver disease, hypothyroidism, alcohol use, and certain medications cause macrocytosis through different mechanisms.

Can macrocytic anemia be cured?

In most cases, yes. Macrocytic anemia caused by B12 deficiency, folate deficiency, alcohol use, or medications usually resolves once the cause is treated. Anemia from liver disease or hypothyroidism improves when the underlying organ function is restored. Macrocytic anemia caused by myelodysplastic neoplasms is more complex and may need long-term treatment, with stem cell transplant being the only curative option for selected patients.

Can you have vitamin B12 deficiency with a normal MCV?

Yes. If a person has B12 deficiency at the same time as iron deficiency or thalassemia, the small and large red blood cells average out to a normal MCV. The clue is often a raised red cell distribution width (RDW) and a peripheral blood smear showing two populations of red cells. Checking actual B12, folate, methylmalonic acid, and ferritin levels is important when symptoms suggest deficiency despite a normal MCV.

Is oral vitamin B12 as good as injections for pernicious anemia?

For most patients, high-dose oral B12 (typically 1,000 micrograms daily) can be effective because around 1 percent of B12 absorbs passively through the gut without needing intrinsic factor. However, intramuscular hydroxocobalamin remains the standard for newly diagnosed pernicious anemia, severe deficiency, and any patient with neurological symptoms. Oral therapy is often used for long-term maintenance once the patient is stable.

How long does macrocytic anemia take to resolve with treatment?

Once B12 or folate replacement starts, the bone marrow responds quickly. A surge in young red blood cells (reticulocytosis) peaks around days 5 to 7. Hemoglobin and MCV usually return to normal within 6 to 8 weeks. Neurological symptoms from B12 deficiency take much longer and, in long-standing cases, may not fully recover.

Which medications can cause macrocytic anemia?

Several drug classes commonly raise the MCV. These include chemotherapy agents (hydroxyurea, methotrexate, 5-fluorouracil, cytarabine, azathioprine), antiretrovirals (zidovudine), anticonvulsants (phenytoin, valproate), proton pump inhibitors and metformin (by reducing B12 absorption over time), and nitrous oxide. An MCV above 130 fL strongly suggests either a drug effect or a myelodysplastic neoplasm rather than a simple vitamin deficiency.

Glossary of Related Medical Terms

• Anisocytosis: Variation in the size of red blood cells, measured by Red Cell Distribution Width (RDW) on a complete blood count.
• Atrophic glossitis: A smooth, shiny, sore tongue caused by loss of small surface bumps (papillae); a classic but late sign of B12 or folate deficiency.
• Erythropoiesis: The process of making red blood cells in the bone marrow.
• Holotranscobalamin (holoTC): The form of B12 actively delivered to cells; a more sensitive marker of B12 deficiency than total serum B12.
• Homocysteine: An amino acid that builds up when either B12 or folate is low.
• Hypersegmented neutrophil: A white blood cell with 6 or more lobes in its nucleus; a hallmark of megaloblastic anemia.
• Intrinsic factor (IF): A protein made by stomach cells that lets vitamin B12 be absorbed in the last part of the small intestine.
• Luspatercept: A newer drug that helps red blood cells mature properly; used to treat anemia in lower-risk myelodysplastic neoplasms.
• Macro-ovalocyte: A large, oval-shaped red blood cell, typical of B12 or folate deficiency.
• Macrocytosis: Red blood cells that are larger than normal (MCV greater than 100 fL).
• Megaloblast: A large, immature red blood cell precursor in the bone marrow with a delayed nucleus; the cell's body grows while its nucleus lags behind.
• Methylmalonic acid (MMA): A chemical that rises in the blood when vitamin B12 is deficient; highly specific for B12 deficiency.
• Myelodysplastic neoplasms (MDS): A group of bone marrow disorders where blood cells are produced but do not mature normally; the new WHO 2022 name for what used to be called myelodysplastic syndromes.
• Nuclear-cytoplasmic asynchrony: When a developing red blood cell's nucleus and cytoplasm grow at different speeds; a hallmark of impaired DNA synthesis.
• Pernicious anemia: An autoimmune cause of B12 deficiency where the immune system destroys stomach cells that make intrinsic factor.
• Reticulocyte: A young red blood cell, slightly larger than mature ones; high counts indicate active red cell production.
• Subacute combined degeneration (SCD): Damage to the spinal cord caused by long-standing vitamin B12 deficiency; can be permanent if untreated.
• Target cell (codocyte): A red blood cell with a central spot of hemoglobin, like a bullseye; often seen in liver disease.

Disclaimer: This article is intended for educational and informational purposes only. It is not intended to be a substitute for informed professional medical advice, diagnosis, or treatment. While the information presented here is derived from credible medical sources and is believed to be accurate and up-to-date, it is not guaranteed to be complete or error-free. See additional information.

References

1. Khoury, J. D., Solary, E., Abla, O., Akkari, Y., Alaggio, R., Apperley, J. F., Bejar, R., Berti, E., Busque, L., Chan, J. K. C., Chen, W., Chen, X., Chng, W. J., Choi, J. K., Colmenero, I., Coupland, S. E., Cross, N. C. P., De Jong, D., Elghetany, M. T., Takahashi, E., … Hochhaus, A. (2022). The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia, 36(7), 1703–1719. https://doi.org/10.1038/s41375-022-01613-1
2. Bernard, E., Tuechler, H., Greenberg, P. L., Hasserjian, R. P., Arango Ossa, J. E., Nannya, Y., Devlin, S. M., Creignou, M., Pinel, P., Monnier, L., Gundem, G., Medina-Martinez, J. S., Domenico, D., Jädersten, M., Germing, U., Sanz, G., van de Loosdrecht, A. A., Kosmider, O., Follo, M. Y., Thol, F., … Papaemmanuil, E. (2022). Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM evidence, 1(7), EVIDoa2200008. https://doi.org/10.1056/EVIDoa2200008
3. Platzbecker, U., Della Porta, M. G., Santini, V., Zeidan, A. M., Komrokji, R. S., Shortt, J., Valcarcel, D., Jonasova, A., Dimicoli-Salazar, S., Tiong, I. S., Lin, C. C., Li, J., Zhang, J., Giuseppi, A. C., Kreitz, S., Pozharskaya, V., Keeperman, K. L., Rose, S., Shetty, J. K., Hayati, S., … Garcia-Manero, G. (2023). Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. Lancet (London, England), 402(10399), 373–385. https://doi.org/10.1016/S0140-6736(23)00874-7
4. National Institute for Health and Care Excellence. (2024). Vitamin B12 deficiency in over 16s: Diagnosis and management (NICE guideline NG239). https://www.nice.org.uk/guidance/ng239
5. Devalia, V., Hamilton, M. S., Molloy, A. M., & British Committee for Standards in Haematology (2014). Guidelines for the diagnosis and treatment of cobalamin and folate disorders. British journal of haematology, 166(4), 496–513. https://doi.org/10.1111/bjh.12959
6. Green, R., Allen, L. H., Bjørke-Monsen, A. L., Brito, A., Guéant, J. L., Miller, J. W., Molloy, A. M., Nexo, E., Stabler, S., Toh, B. H., Ueland, P. M., & Yajnik, C. (2017). Vitamin B₁₂ deficiency. Nature reviews. Disease primers, 3, 17040. https://doi.org/10.1038/nrdp.2017.40
7. Garakani, A., Jaffe, R. J., Savla, D., Welch, A. K., Protin, C. A., Bryson, E. O., & McDowell, D. M. (2016). Neurologic, psychiatric, and other medical manifestations of nitrous oxide abuse: A systematic review of the case literature. The American journal on addictions, 25(5), 358–369. https://doi.org/10.1111/ajad.12372
8. American Diabetes Association Professional Practice Committee (2024). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. Diabetes care, 47(Suppl 1), S158–S178. https://doi.org/10.2337/dc24-S009
9. Zandecki, M., Genevieve, F., Gerard, J. and Godon, A. (2007). Spurious counts and spurious results on haematology analysers: a review. Part II: white blood cells, red blood cells, haemoglobin, red cell indices and reticulocytes. International Journal of Laboratory Hematology, 29: 21-41. https://doi.org/10.1111/j.1365-2257.2006.00871.x
10. Wazir, S. M., & Ghobrial, I. (2017). Copper deficiency, a new triad: anemia, leucopenia, and myeloneuropathy. Journal of community hospital internal medicine perspectives, 7(4), 265–268. https://doi.org/10.1080/20009666.2017.1351289
11. Chandra, S., Tripathi, A. K., Mishra, S., Amzarul, M., & Vaish, A. K. (2012). Physiological changes in hematological parameters during pregnancy. Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 28(3), 144–146. https://doi.org/10.1007/s12288-012-0175-6